• Devonian Health Group integrated validated chemical fingerprinting and a cell-based potency assay into Thykamine manufacturing quality control.
• HPLC-MS method validated by Chromak Research; U937 cell assay validated by Pacific BioLabs using MIP-1β as anti-inflammatory marker.
• External testing to continue on future batches, targeting independent verification of chemical consistency and biological activity.
• NMR batch analyses showed more than 98% reproducibility, supporting manufacturing consistency for the botanical drug candidate.
• Upgrade positions Thykamine for later-stage development by tightening batch-to-batch controls aligned with FDA botanical drug expectations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Devonian Health Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: MO37112) on September 01, 2026, and is solely responsible for the information contained therein.